Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known. Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with community-acquired p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal Jg. 45; H. 6; S. 1632
Hauptverfasser: Rodrigo, Chamira, Bewick, Thomas, Sheppard, Carmen, Greenwood, Sonia, Mckeever, Tricia M, Trotter, Caroline L, Slack, Mary, George, Robert, Lim, Wei Shen
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.06.2015
Schlagworte:
Aged
Aged, 80 and over
Cohort Studies
Community-Acquired Infections - epidemiology
Community-Acquired Infections - prevention & control
Female
Hospitalization - trends
Humans
Incidence
Male
Middle Aged
Pneumococcal Vaccines - therapeutic use
Pneumonia, Pneumococcal - epidemiology
Pneumonia, Pneumococcal - microbiology
Pneumonia, Pneumococcal - prevention & control
Prospective Studies
Serogroup
Streptococcus pneumoniae - isolation & purification
ISSN:1399-3003, 1399-3003
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known. Beginning in 2008, a 5-year prospective cohort study of adults admitted to hospital with community-acquired pneumonia (CAP) was conducted. Pneumococcal serotype was established using a validated multiplex immunoassay (Bio-Plex; Bio-Rad, Hercules, CA, USA). The overall incidence for hospitalised CAP and pneumococcal CAP was 79.9 (95% CI 76.6-83.3) and 23.4 (95% CI 21.6-25.3) per 100,000 population, respectively. A decline in CAP (incidence rate ratio (IRR) per year 0.96, 95% CI 0.94-0.99; p=0.016) and pneumococcal CAP (IRR per year 0.84, 95% CI 0.80-0.89; p<0.001) was observed over the 5-year period of the study. Between the pre- and post-PCV13 periods of the study, the incidence of CAP due to serotypes included in the PCV7 declined by 88% (IRR 0.12, 95% CI 0.08-0.20; p<0.001), and CAP due to the additional 6 serotypes in PCV13 declined by 30% (IRR 0.70, 95% CI 0.51-0.96; p=0.024). Incidence of adult pneumococcal pneumonia declined over the last 5 years, with serotypes included in PCV13 declining post-PCV13 introduction, indicating early herd protection effects from PCV13 infant vaccination on adult non-bacteraemic disease. These effects may accrue over the coming years with implications for national pneumococcal vaccination policies in adults.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1399-3003
1399-3003
DOI:10.1183/09031936.00183614